Ricerc@Sapienza

It is now widely accepted that oxysterols are more than metabolic intermediates but are actually bona fide lipid mediators. To qualify as a bona fide lipid mediator, a lipid compound should meet three conditions. First to be endogenous, second to have its levels altered depending on the physiological or pathological situation, and third to induce a signaling response when its levels are altered. As is evident from the papers published in this Special issue, oxysterols largely qualify as bona fide lipid mediators.

Objectives: The aim of this study was to evaluate the chronic effects of mesoglycan on the vascular
remodeling in patients with metabolic syndrome (Mets).
Background: MetS is defined by a clustering of vascular risk factors that require both pharmacologic
and non-pharmacologic interventions, including body weight reductions and physical activity. The
correction of vascular remodeling associated with MetS has lately received increasing interest.
Methods: Thirty consecutive ambulatory patients affected by MetS were 2:1 randomized in a doubleblind

Background: To date, very little information is available concerning the relationship between acanthosis nigricans (AN) and infection with human immunodeficiency virus type 1 (HIV-1).

OBJECTIVE:
Metabolic syndrome (MetS) is defined as a spectrum of conditions associated with an increased risk of developing CVD and type 2 diabetes. MetS include: hyperglycemia, hypertension, visceral obesity, dyslipidemia with elevated values of triglycerides (TG) and low levels of HDL. The aim of this review is to provide current knowledge of the relationship between MetS, its components and peri-implant diseases.

BACKGROUND: The correlation of peri-implantitis with systemic diseases is still highly debated and controversial in literature. The objective of this work was to evaluate the possible association between peri-implant diseases and metabolic syndrome.METHODS: In this case-control study, subjects healthy or affected by metabolic syndrome, with at least one dental implant with > 5 years of functional loading were screened to detect peri-implant health or diseases.

Over the years, only few authors have studied the association of systemic conditions with peri-implantitis. The aim of this study is to detect frequency and severity of peri-implant diseases among an Italian population of patients affected by metabolic syndrome (MetS).METHODS:

INTRODUCTION: Currently, abdominal obesity has reached an epidemic stage and obesity represents an important challenge for worldwide health authorities. Epidemiologic studies have demonstrated that the stone risk incidence increases with Body Mass Index, through multiple pathways. Metabolic syndrome and diabetes are associated with an increased renal stones disease incidence. The aim of this systematic review was to investigate the prevalence, morbidity, risk factors involved in the association between obesity and urolithiasis.

Rationale: Studies suggest a relation between exposure to air particulate matter (PM)2.5 pollution and greater cardiovascular morbidity, as well as increased risk for obesity and diabetes. We aimed to identify association(s) between nutritional and metabolic status and exposure to environmental pollution in a cohort of policemen exposed to high levels of air pollution. Methods: We considered adult municipal policemen, working in an urban area at high-traffic density with documented high levels of air PM2.5 (exposed group) compared to non-exposed policemen.

Mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of heart failure and hypertension, mainly due to their natriuretic and anti-fibrotic mode of action. Rodent studies have shown that MRAs can prevent adverse metabolic consequences of obesity but an elucidation of underlying molecular mechanisms is missing. Here, we investigated metabolic effects of the novel non-steroidal MRA finerenone (FIN) in a mouse model of high-fat diet (HFD)-induced obesity and the signaling pathways activated by MR antagonism at level of interscapular brown adipose tissue (iBAT).